Cardiovascular Branch, Division of Intramural Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD (J.M.K., M.Y.C., C.G.B., A.M.S., X.T., T.R., R.J.L.).
Structural Heart and Valve Center, Emory University Hospital, Atlanta, GA (A.B.G., V.C.B., G.P.).
Circ Cardiovasc Interv. 2021 May;14(5):e010238. doi: 10.1161/CIRCINTERVENTIONS.120.010238. Epub 2021 May 18.
Coronary artery obstruction is a rare, devastating complication of transcatheter aortic valve replacement. Transcatheter electrosurgical aortic leaflet laceration (Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction [BASILICA]) is a novel technique to prevent coronary artery obstruction. We report the 1-year outcomes of the BASILICA trial. Primary end points of 30-day success and safety have been reported previously.
The BASILICA trial was a prospective, multicenter, single-arm safety and feasibility study. Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and high risk of coronary artery obstruction, were included. End points at 1 year included death, stroke, and myocardial infarction. Source data was independently verified and end points independently adjudicated.
Thirty subjects were enrolled between February 2018 and July 2018. At 30 days, BASILICA was successful in 28 subjects (93.3%), there were 3 strokes (10%), including 1 disabling stroke (3.3%), 1 death (3.3%), and 1 periprocedural myocardial infarction (3.3%). Between 30 days and 1 year, there were no additional strokes, no myocardial infarction, and 2 deaths (10% 1-year mortality). No subject needed repeat intervention for aortic valve or coronary disease. Two subjects had infective endocarditis (6.7%), but neither was isolated to the aortic valve. There were no hospital admissions for heart failure. Fourteen (46.7%) subjects required repeat hospital admission for other causes. Aortic valve gradients on echocardiography, New York Heart Association functional class, and Kansas City Cardiomyopathy Questionnaire scores improved from baseline to 30 days and were maintained at 1 year.
In these subjects with multiple comorbidities and restrictive anatomy that underwent transcatheter aortic valve replacement, there was no late stroke, myocardial infarction, or death related to BASILICA. Mitigation of coronary obstruction remained intact at 1 year and was not related to recurrent readmission. These results are reassuring for patients and physicians who wish to avoid the long-term complications related to snorkel stenting.
URL: https://www.clinicaltrials.gov; Unique identifier: NCT03381989.
经导管主动脉瓣置换术后发生冠状动脉阻塞是一种罕见且破坏性极大的并发症。经导管电外科主动脉瓣叶切开术(生物假体或原生主动脉瓣片切开术以预防医源性冠状动脉阻塞[BASILICA])是一种预防冠状动脉阻塞的新方法。我们报告了 BASILICA 试验的 1 年结果。先前已经报告了 30 天成功率和安全性的主要终点。
BASILICA 试验是一项前瞻性、多中心、单臂安全性和可行性研究。该研究纳入了患有严重原生或生物假体主动脉瓣疾病、手术风险高或极高、以及存在冠状动脉阻塞高风险的患者。1 年时的终点包括死亡、卒中和心肌梗死。原始数据经过独立验证,终点由独立的裁判裁定。
2018 年 2 月至 7 月期间,共纳入 30 名患者。在 30 天时,BASILICA 在 28 名患者(93.3%)中获得成功,有 3 例(10%)发生卒中,包括 1 例致残性卒中(3.3%)、1 例死亡(3.3%)和 1 例围手术期心肌梗死(3.3%)。在 30 天至 1 年期间,没有发生其他卒中、心肌梗死和 2 例死亡(10%的 1 年死亡率)。没有患者需要再次介入治疗主动脉瓣或冠状动脉疾病。有 2 例(6.7%)发生感染性心内膜炎,但均未累及主动脉瓣。没有患者因心力衰竭而住院。有 14 例(46.7%)患者因其他原因再次住院。经超声心动图检查,主动脉瓣梯度、纽约心脏协会功能分级和堪萨斯城心肌病问卷评分均从基线改善至 30 天,并在 1 年时保持稳定。
在这些患有多种合并症且解剖结构受限的患者中,经导管主动脉瓣置换术后未发生与 BASILICA 相关的迟发性卒中和心肌梗死,也未发生死亡。1 年后,冠状动脉阻塞的缓解情况仍然完好,且与再次住院无关。这些结果使希望避免与使用导丝支架相关的长期并发症的患者和医生感到安心。